hemostatikum haemocer
biocer entwicklungs gmbh ludwig-thoma-strasse 36c bayreuth nemecko -
hemostatikum haemocer patch
biocer entwicklungs gmbh ludwig-thoma-strasse 36c bayreuth nemecko -
hemostatikum haemocer plus
biocer entwicklungs gmbh ludwig-thoma-strasse 36c bayreuth nemecko -
matrica hemostatická surgiflo haemostatic matrix/kit with thrombin
ferrosan medical devices a/s sydmarken 5 dk-2860 soeborg dánsko -
špongia hemostatická surgiflo haemostatic matrix plus flextip
ferrosan medical devices a/s sydmarken 5 dk-2860 soeborg dánsko -
aplikátor endoskopický haemocer
biocer entwicklungs gmbh ludwig-thoma-strasse 36c bayreuth nemecko -
dicural
pfizer limited - difloxacín - antibakteriálne pre systémové použitie, antiinfektíva na systémové použitie - turkeys; dogs; cattle; chicken - sliepky:pre liečbu chronických respiračných infekcií spôsobených citlivé kmene escherichia coli a mycoplasma gallisepticum. morky: na liečbu chronických respiračných infekcií spôsobených citlivými kmeňmi escherichia coli a mycoplasma gallisepticum. tiež na liečbu infekcií spôsobených baktériou pasteurella multocida. psy: na liečbu akútnych nekomplikovaných infekcií močových ciest spôsobených escherichia coli alebo staphylococcus spp. a povrchná pyodermia spôsobená staphylococcus intermedius. dobytok:pre liečbu hovädzieho dobytka choroby dýchacích ciest (doprava horúčka, teľa zápal pľúc) spôsobené jeden alebo zmiešané infekcie s pasteurella haemolytica, pasteurella multocida a / alebo mycoplasma spp.
prothromplex nf 600 iu
baxalta innovations gmbh, rakúsko - koagulačné faktory ix, ii, vii a x v kombinácii - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
endoxan
baxter slovakia s.r.o., slovensko - cyklofosfamid - 44 - cytostatica
ultomiris
alexion europe sas - ravulizumab - hemoglobinúria, paroxysmálna - selektívne imunosupresíva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.